AstraZeneca

Kirsty Blackman Excerpts

Monday 3rd February 2025 Commons Chamber

[Chris Bryant]

Not only have we set aside £520 million precisely to be able to invest in the life sciences industry with an innovation fund, we are very keen to work with specific businesses to understand how they can make more secure, long-term investment. The single most important thing for most people making an investment in the UK is whether they believe there is political, fiscal and financial stability in the UK. That is what we are absolutely determined to deliver. My hon. Friend makes a very good point about those who are immunosuppressed for all sorts of different reasons, whether their medication or a condition. I will take that point back to the Department.

[Kirsty Blackman (Aberdeen North) (SNP)]

The Chancellor said that economic growth is the most important thing and this was an opportunity to get some of that economic growth. This was an opportunity to get something over the line and the UK Government failed to deliver it. How can the House and the public trust anything the UK Government say? How can they say that this is the founding mission if they then fail to deliver for a region that could really do with that economic growth?

[Chris Bryant]

The thing is that spending taxpayers’ money has to be proven to be good value for money. That is why, whenever we are making an investment such as this, we have to make sure it delivers more return on investment than £1 for £1. When AstraZeneca made the decision to cut the R&D part of its budget from £150 million to £90 million, it made sense for the UK Government to look again at the amount of money we could legitimately put in on behalf of the taxpayer. If the hon. Lady had been in my place, I think she would have made exactly the same decision.